{"gene":"NF1","run_date":"2026-06-10T05:19:52","timeline":{"discoveries":[{"year":1993,"finding":"Full-length type I NF1 (neurofibromin) coinjected with wild-type Ras abolished Ras-induced AP-1 reporter gene expression in fibroblasts, whereas type II GAP did not; serum-stimulated DNA synthesis was reduced by type I GAP but not by type I NF1, demonstrating that NF1 and GAP have distinct in vivo biological activities despite similar in vitro GTPase-activating properties toward Ras.","method":"Microinjection of purified proteins into fibroblasts, AP-1-controlled reporter gene assay, DNA synthesis measurement","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — direct in vitro/cell-injection assay with functional readout, single lab, single study","pmids":["8455625"],"is_preprint":false},{"year":1995,"finding":"The GAP-related domain (GRD) of neurofibromin encoded by exons 20–27a is required for GTPase-activating activity toward Ras; the missense mutation R1391S in the GRD reduces GAP activity approximately 300-fold compared to wild-type NF1 GRD, as measured by in vitro GAP assay after site-directed mutagenesis and expression.","method":"Site-directed mutagenesis, in vitro expression, GAP activity assay","journal":"Human genetics","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with mutagenesis and direct enzymatic assay; finding consistent with multiple studies","pmids":["9003501"],"is_preprint":false},{"year":1995,"finding":"NF1 type 1 and type 2 isoforms (differing by the 21-amino-acid exon 23a insertion) are differentially expressed: type 1 predominates in CNS neurons and is associated with microtubule binding, while type 2 predominates in glial cells and during early embryogenesis; type 2 neurofibromin does not associate with brain cytoplasmic microtubules in the same fashion as type 1, suggesting isoform-specific functional differences.","method":"Northern blot, in situ hybridization, Western blot analysis of tissue fractions, microtubule co-fractionation assay","journal":"Cell growth & differentiation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (Northern, ISH, Western, fractionation) in single lab","pmids":["7794799"],"is_preprint":false},{"year":1995,"finding":"During mouse embryogenesis, type 2 NF1 mRNA predominates before embryonic day 10, after which type 1 NF1 mRNA becomes predominant; type 2 neurofibromin is not associated with cytoplasmic microtubules in brain in the same fashion as type 1, suggesting the developmental isoform switch has functional consequences for microtubule interaction.","method":"Northern blot, Western blot, cytoplasmic microtubule co-fractionation in mouse brain","journal":"Progress in brain research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple methods (Northern, Western, fractionation), single lab","pmids":["7568895"],"is_preprint":false},{"year":1996,"finding":"Neurofibromin expression is upregulated in reactive astrocytes in response to cerebral ischemia (both focal and global models in rats), co-incident with GFAP upregulation, indicating a role for neurofibromin in injury-induced growth regulatory pathways in astrocytes.","method":"Immunohistochemistry in rat focal and global ischemia models, Western blot","journal":"Journal of neuroscience research","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, single method (IHC/Western), no direct functional manipulation of NF1","pmids":["8820972"],"is_preprint":false},{"year":1996,"finding":"The NF1 alternative splicing of exons 23a/23b in the GRD region can be modulated by extrinsic factors in PC12 cells: nerve growth factor and dexamethasone increase the type I isoform concurrent with decreased proliferation; cycloheximide treatment reveals an additional transcript (type III). Dexamethasone effect is RNA-synthesis-dependent.","method":"RT-PCR isoform analysis in PC12 cells with pharmacological treatments (NGF, dexamethasone, cycloheximide), actinomycin D block","journal":"Experimental cell research","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, descriptive RT-PCR without direct functional validation of isoform-specific effects","pmids":["8892969"],"is_preprint":false},{"year":2000,"finding":"GM-CSF plays a central role in establishing and maintaining the myeloproliferative disorder (MPD) driven by Nf1 deficiency: hematopoietic cells doubly deficient in Nf1 and Gmcsf fail to induce MPD in recipients, but remain hypersensitive to exogenous GM-CSF, demonstrating that Nf1-deficient myeloid cells require GM-CSF signaling for their excessive proliferation in vivo.","method":"Genetic intercross of Nf1 and Gmcsf knockout mice, adoptive transfer of fetal liver hematopoietic cells, methylcellulose colony assay, exogenous GM-CSF challenge","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with double-knockout rescue, adoptive transfer, multiple orthogonal approaches, in vivo and in vitro readouts","pmids":["10678181"],"is_preprint":false},{"year":2001,"finding":"In Schwann cells, Nf1 tumor suppressor function antagonizes the accumulation of cAMP and the expression of cyclin D1: ectopic expression of cyclin D1 using an inducible retroviral vector bypasses the G1 phase requirement for cAMP in Schwann cell proliferation, and loss of Nf1 increases cAMP and cyclin D1 levels, placing cyclin D1 as a downstream effector of Nf1-dependent growth control.","method":"Inducible retroviral expression of cyclin D1 in Schwann cells, cAMP measurement, cyclin D1 immunoblot, BrdU proliferation assay, Nf1-/- vs. wild-type Schwann cell comparison","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple methods (retroviral overexpression, genetic KO cells, biochemical measurements), direct epistasis established in primary cells","pmids":["11160381"],"is_preprint":false},{"year":2002,"finding":"Loss of NF1 specifically in the Schwann cell lineage (using cre/lox conditional allele driven by Schwann cell-specific Krox20/Egr2-Cre) is sufficient to generate neurofibromas; however, complete tumorigenesis also requires NF1 heterozygosity in the surrounding non-neoplastic microenvironment.","method":"Conditional Schwann cell-specific Nf1 knockout mouse (cre/lox), tumor histology, genetic epistasis with germline Nf1+/- background","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean conditional KO with defined cell-type specificity, complemented by haploinsufficiency epistasis experiment, replicated by subsequent labs","pmids":["11988578"],"is_preprint":false},{"year":2006,"finding":"CTCF mediates interchromosomal colocalization between the Igf2/H19 imprinting control region on chromosome 7 and the Wsb1/Nf1 locus on chromosome 11; deletion of the maternal ICR or omission of CTCF abrogates this association and alters Wsb1/Nf1 gene expression, establishing CTCF-dependent long-range transcriptional regulation of NF1.","method":"Modified chromosome conformation capture (3C), fluorescence in situ hybridization (FISH), CTCF knockdown, ICR deletion mouse model, RT-PCR of Wsb1/Nf1 expression","journal":"Science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — 3C and FISH with functional readout (gene expression), single lab, two orthogonal methods","pmids":["16614224"],"is_preprint":false},{"year":2008,"finding":"Nf1 heterozygosity in bone marrow-derived cells (specifically mast cells) in the tumor microenvironment is sufficient to allow neurofibroma progression when combined with Schwann cell Nf1 deficiency; genetic or pharmacologic attenuation of c-kit signaling in Nf1+/- hematopoietic cells diminishes neurofibroma initiation and progression, identifying mast cells and c-kit signaling as critical mediators.","method":"Bone marrow transplantation between Nf1 genotypes, conditional Schwann cell Nf1 KO (DhhCre), c-kit genetic intercross, imatinib pharmacological inhibition, tumor histology and quantification","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic rescue/epistasis with bone marrow transfer, pharmacological validation, multiple orthogonal approaches","pmids":["18984156"],"is_preprint":false},{"year":2008,"finding":"Ras/Raf/ERK signaling drives de-differentiation of myelinating Schwann cells, a process relevant to NF1-associated tumor formation; Schwann cells lacking Nf1 show elevated Ras-ERK activity that promotes de-differentiation.","method":"Conditional NF1 knockout Schwann cells, Ras/ERK pathway assays, Schwann cell de-differentiation markers","journal":"Cell cycle","confidence":"Low","confidence_rationale":"Tier 3 / Weak — review/commentary-type abstract with limited primary experimental detail provided","pmids":["15467460"],"is_preprint":false},{"year":2009,"finding":"Skin-derived precursor (SKP) stem/progenitor cells residing in the dermis serve as the cell of origin for dermal neurofibromas upon loss of Nf1; non-neoplastic cells in the tumor microenvironment provide additional signals essential for neurofibromagenesis.","method":"Conditional Nf1 loss in SKPs (P0-Cre), tumor histology, lineage tracing, co-culture/transplantation experiments","journal":"Cell stem cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO with lineage tracing and transplantation, single lab, multiple methods","pmids":["19427294"],"is_preprint":false},{"year":2008,"finding":"Nf1 loss of function amplifies an EGFR-dependent peripheral nerve progenitor pool in embryonic dorsal root ganglia; these Nf1-null progenitors are hypersensitive to growth factors, confer tumorigenesis in vivo, and human NF1 neurofibromas contain EGFR+/P75+ cells that form spheres and give rise to neurofibroma-like lesions in nude mice.","method":"In vitro sphere-formation assay, genetic (DhhCre;Nf1fl/fl) and pharmacologic (EGFR inhibition) tools, prospective FACS isolation of human EGFR+/P75+ cells, xenograft assay in nude mice","journal":"Cell stem cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (genetic KO, pharmacological, xenograft, human primary cells), single lab with comprehensive experimental design","pmids":["19041782"],"is_preprint":false},{"year":2010,"finding":"NF1 null states in adult AML are associated with increased Ras-bound GTP; shRNA-mediated NF1 suppression in primary AML blasts with wild-type NF1 facilitates colony formation; NF1-null AML blasts show selective sensitivity to rapamycin-induced apoptosis, identifying mTOR as a survival dependency in NF1-null AML.","method":"SNP array, NF1 sequencing, Ras-GTP pulldown assay, shRNA knockdown, colony formation in methylcellulose, rapamycin treatment of primary blasts and CD34+/CD38- cells","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Ras-GTP biochemical assay plus shRNA functional validation plus ex vivo pharmacological, single lab","pmids":["20505189"],"is_preprint":false},{"year":2010,"finding":"In Nf1+/- mice, disruption of Ras regulation of inhibitory (GABAergic) neuronal networks is critical to the etiology of cognitive deficits; Nf1 haploinsufficiency increases GABA neurotransmitter pathway activity and MAPK signaling in neurons, and these phenotypes are rescued by pharmacological or genetic reduction of MAPK pathway activity.","method":"Nf1+/- mouse behavioral assays, electrophysiology, MAPK pathway inhibitors (lovastatin), genetic epistasis","journal":"Annual review of neuroscience","confidence":"Low","confidence_rationale":"Tier 3 / Weak — review article summarizing prior findings; primary experimental data not described in this abstract","pmids":["20345245"],"is_preprint":false},{"year":2010,"finding":"Nf1-/- Schwann cell-conditioned medium promotes increased degranulation of Nf1+/- mast cells compared with wild-type mast cells via secretion of Kit ligand (SCF); this effect is mediated by hyperactivation of the p21Ras-PI3K pathway, as demonstrated by genetic intercross and pharmacological inhibition.","method":"Schwann cell conditioned medium treatment of mast cells, degranulation assay, genetic Nf1/PI3K intercrosses, pharmacological PI3K inhibition, in vitro and in vivo measurements","journal":"The American journal of pathology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and pharmacological approaches combined with functional cell assays, single lab","pmids":["21037083"],"is_preprint":false},{"year":2011,"finding":"Perinatal or adult induction of Nf1 loss in the Schwann cell lineage using tamoxifen-inducible PlpCre each cause neurofibroma formation; perinatal loss yields small neurofibromas late in life while adult loss causes large neurofibromas with earlier onset; EGFP reporter identifies that Nf1 loss in S100β+ myelinating and p75+ peripheral nerve Schwann cells but not GFAP+ non-myelinating Schwann cells contributes to tumors. A non-cell-autonomous effect of Nf1-deleted microenvironment on lympho-hematopoietic expansion was also identified.","method":"Tamoxifen-inducible PlpCre;Nf1fl/fl conditional knockout, conditional EGFP reporter lineage tracing, histological analysis, tumor timing/size quantification","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional inducible KO with lineage tracing, single lab, two timing conditions tested","pmids":["21551249"],"is_preprint":false},{"year":2012,"finding":"NF1 mutations cooperate with BRAF mutations in melanomagenesis by preventing oncogene-induced senescence (OIS); Nf1 mutations suppress Braf-induced senescence in a genetically engineered mouse model and function by deregulating both PI3K and ERK pathways; NF1 ablation decreases sensitivity of melanoma cell lines to BRAF inhibitors.","method":"Genetically engineered mouse model (BRAF+Nf1 mutations), senescence assays (SA-β-gal), proliferation assays, PI3K/ERK pathway biochemistry, BRAF inhibitor sensitivity assays in cell lines","journal":"Cancer discovery","confidence":"High","confidence_rationale":"Tier 2 / Strong — mouse genetic model plus mechanistic pathway analysis plus human cell line validation, multiple orthogonal methods","pmids":["23171796"],"is_preprint":false},{"year":2013,"finding":"Nf1 deficiency in muscle results in neonatal lethality in muscle-specific knockouts; the limb-specific Nf1Prx1-/- conditional knockout shows 10-fold increased muscle triglyceride content, increased activities of oxidative metabolism enzymes, elevated fatty acid synthase and leptin expression, and decreased fatty acid transporters, establishing NF1 as essential for normal muscle energy metabolism.","method":"Conditional muscle-specific Nf1 knockout mice (Nf1muscle-/- and Nf1Prx1-/-), electron microscopy, Oil Red O staining, enzyme activity assays, Western blot","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple tissue-specific conditional KO models with orthogonal biochemical assays, single lab","pmids":["24163128"],"is_preprint":false},{"year":2013,"finding":"Ras-Erk signaling in neurofibromin-deficient macrophages is the aberrant pathway responsible for enhanced neointima formation in NF1: Nf1+/- macrophages show enhanced Erk signaling in vitro; in vivo Nf1+/- mice show increased intimal proliferation after carotid artery injury; MEK inhibitor PD0325901 reduces Nf1+/- neointima formation to wild-type levels without affecting PI3K signaling.","method":"Carotid artery injury model in Nf1+/- mice, ERK and PI3K phosphorylation assays, macrophage migration assays, PD0325901 pharmacological inhibition, morphometric neointima analysis","journal":"The American journal of pathology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo pharmacological rescue with pathway biochemistry, single lab, multiple readouts","pmids":["24211110"],"is_preprint":false},{"year":2014,"finding":"Neurofibromin regulation of cAMP in neurons requires RAS activation followed by atypical PKC-zeta activation, which drives GRK2-mediated Gαs inactivation; this was established using iPSC-derived NF1 patient neural progenitors and Nf1 genetically engineered mice, demonstrating that MEK/AKT pathways are not involved in the RAS→cAMP connection in neurons.","method":"iPSC-derived neural progenitors from NF1 patients, Nf1 genetically engineered mice, cAMP measurement, PKC-zeta inhibition, GRK2 knockdown, MEK/AKT inhibitors","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — human iPSC model plus mouse model with pharmacological dissection of pathway; multiple orthogonal approaches in single comprehensive study","pmids":["25070947"],"is_preprint":false},{"year":2014,"finding":"Reduced NF1/neurofibromin expression impairs RAS-ERK signal attenuation downstream of mutant EGFR; erlotinib fails to fully inhibit RAS-ERK signaling when neurofibromin levels are reduced; MEK inhibitor treatment restores erlotinib sensitivity in neurofibromin-deficient lung cancer cells.","method":"Genome-wide siRNA screen in human lung cancer cells, Western blot (neurofibromin, pERK), MEK inhibitor combination treatment, murine EGFR-driven lung adenocarcinoma model","journal":"Cancer discovery","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genome-wide siRNA screen validated with biochemical pathway analysis and pharmacological rescue, mouse model confirmation","pmids":["24535670"],"is_preprint":false},{"year":2014,"finding":"Nf1+/- mice show a selective social learning deficit associated with greater activation of the MAPK pathway in amygdala and frontal cortex neurons; Nf1+/- amygdala exhibits aberrant glutamate and GABA neurotransmission, deficits in LTP, and specific disruptions in ADAM22 and HSP70 protein expression; all amygdala disruptions and social behavior deficits are rescued by deletion of Pak1 or pharmacological Pak1 blockade in the amygdala.","method":"Nf1+/- mouse behavioral testing, amygdala LTP electrophysiology, MAPK pathway Western blots, Pak1 genetic intercross, stereotaxic pharmacological injection of Pak1 inhibitors","journal":"Nature neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis (Pak1 KO rescue) plus pharmacological rescue with multiple behavioral, electrophysiological, and biochemical readouts","pmids":["25242307"],"is_preprint":false},{"year":2014,"finding":"MAF is an NF1-regulated transcription factor downstream of RAS/MAPK/AP-1 signaling; MAF re-expression promotes glial differentiation markers and affects MPNST cell death and growth; chronically elevated MAF enhances MPNST tumor growth in vivo through mTOR pathway activation via DEPTOR regulation; RAD001 blocks MAF-mediated tumor growth, establishing a RAS-MAPK→MAF→mTOR crosstalk mechanism.","method":"Transcriptome analysis, RT-PCR/Western blot validation, MAF overexpression in MPNST cell lines (inducible), in vivo tumor xenografts, RAD001 treatment, DEPTOR expression analysis","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transcriptome-driven discovery with in vitro and in vivo functional validation plus pharmacological intervention, single lab","pmids":["24509877"],"is_preprint":false},{"year":2016,"finding":"Different NF1 germline mutations (R681X vs. G848R) result in different levels of neurofibromin expression and different optic glioma phenotypes; R681X mutation causes optic glioma formation with increased microglia infiltration and JNK/Ccl5/AKT activation in the microenvironment, while G848R does not; primary astrocytes with R681X show increased basal proliferation comparable to neo-CKO astrocytes, establishing germline mutation type as a cell-autonomous and stromal determinant of glioma development.","method":"Genetically engineered mice with patient-derived Nf1 mutations (R681X and G848R conditional KO), optic nerve volumetry/GFAP/BrdU immunostaining, retinal ganglion cell death assay, microglia quantification, phosphoprotein Western blots, primary astrocyte cultures","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — two patient-derived knock-in mutations compared side-by-side with multiple cell-autonomous and stromal readouts in genetically engineered mice","pmids":["26908603"],"is_preprint":false},{"year":2017,"finding":"Nf1 deficiency in mature oligodendrocytes causes progressive myelin decompaction and behavioral abnormalities mediated by aberrant Notch activation; blocking Notch, upstream MAPK, or nitric oxide signaling rescues myelin defects in hemizygous Nf1 mutants; gamma secretase inhibition rescues aberrant behavior; active Notch is increased in NF1 patient white matter, establishing Notch as a downstream effector of neurofibromin in oligodendrocyte myelin maintenance.","method":"Oligodendrocyte-specific conditional Nf1 knockout mice, myelin ultrastructure analysis, behavioral testing, Notch pathway inhibition (gamma secretase inhibitor), MEK inhibitor, NOS inhibitor, patient white matter immunostaining","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific conditional KO with pharmacological rescue using multiple pathway inhibitors and human patient tissue validation","pmids":["28423318"],"is_preprint":false},{"year":2017,"finding":"NF1 deficiency in fracture calluses leads to elevated β-catenin protein and activation of β-catenin-mediated signaling, resulting in delayed and fibrous fracture repair; pharmacological inhibition of β-catenin signaling with Nefopam rescues osteoblastic colony formation, bone content, and cartilage in Nf1-/- fracture calluses.","method":"Nf1-/- conditional mouse fracture model, β-catenin/Axin2 immunostaining and Western blot in patient and mouse tissue, bone marrow stromal cell osteoblast colony assay, histomorphometry of fracture callus, Nefopam pharmacological treatment","journal":"Bone","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO model with biochemical pathway evidence and pharmacological rescue, human tissue corroboration, single lab","pmids":["28254468"],"is_preprint":false},{"year":2018,"finding":"Neurofibromin interacts with CRMP2 and uncouples CRMP2 from syntaxin 1A; loss of neurofibromin (NF1) frees CRMP2 to interact with both syntaxin 1A and CaV2.2, increasing CGRP release and causing pain hypersensitivity; CRISPR/Cas9 editing of Nf1 dysregulates NaV1.7 and CaV2.2, and the CRMP2-derived peptide CNRP1 targeting the CRMP2-neurofibromin interface reverses these ion channel dysregulations and thermal hyperalgesia.","method":"Co-immunoprecipitation (CRMP2/neurofibromin/syntaxin 1A/CaV2.2), CRISPR/Cas9 Nf1 editing in rats, neurotransmitter (CGRP) release assay, electrophysiology (NaV1.7, CaV2.2), thermal hyperalgesia behavioral assay, CNRP1 peptide rescue","journal":"Neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — Co-IP interaction network plus CRISPR KO plus peptide rescue plus electrophysiology and behavior, multiple orthogonal methods","pmids":["29655575"],"is_preprint":false},{"year":2018,"finding":"Nf1 heterozygosity in the microenvironment accelerates formation of benign tumors but impairs malignant transformation, as shown in two orthogonal mouse models; an Nf1+/- microenvironment is tumor-promoting for benign lesions but antagonistic for progression to malignancy, reconciling the roles of NF1 in NF1-syndrome and sporadic cancers.","method":"Two independent mouse tumor models (NF1-related and non-NF1-related), conditional genetics, tumor incidence and progression analysis, human tumor data analysis","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two orthogonal genetic mouse models with tumor initiation and progression readouts, single lab","pmids":["30479396"],"is_preprint":false},{"year":2019,"finding":"Full-length neurofibromin forms a high-affinity dimer in vitro and in human cells; biophysical analyses (SEC-MALS, SAXS, SANS, analytical ultracentrifugation) and negative-stain EM reveal the overall dimer architecture; mixing N- and C-terminal protein domains reconstitutes dimer-like structures capable of GTPase activation in vitro; co-expression of the two domains in human cells recapitulates full-length neurofibromin activity.","method":"SEC-MALS, small-angle X-ray and neutron scattering, analytical ultracentrifugation, negative-stain EM, in vitro GTPase activation assay, co-IP in human cells, reconstitution from N- and C-terminal fragments","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple structural and biophysical methods with in vitro reconstitution and functional validation of GTPase activity; comprehensive single-study design","pmids":["31836666"],"is_preprint":false},{"year":2021,"finding":"Germline Nf1 mutation in retinal neurons causes aberrantly increased shedding of neuroligin-3 (NLGN3) within the optic nerve in response to retinal neuronal activity; NLGN3 shedding is required for Nf1-driven optic glioma initiation and progression; light deprivation prevents optic glioma formation; genetic Nlgn3 loss or pharmacological NLGN3 shedding inhibition blocks optic glioma formation, establishing neuronal activity–driven NLGN3 shedding as an obligate mechanism downstream of Nf1 mutation.","method":"Authenticated Nf1 mouse OPG model, light deprivation experiment, NLGN3 ELISA in optic nerve, Nlgn3 genetic KO rescue, pharmacological ADAM10 inhibitor (NLGN3 shedding inhibition), tumor volume MRI quantification","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic model plus two independent rescue approaches (genetic KO and pharmacological) plus mechanistic biochemical readout, published in high-impact peer-reviewed journal","pmids":["34040258"],"is_preprint":false},{"year":2023,"finding":"Patient variants in NF1 codons 844–848 cause protein instability and exert a dominant-negative effect by destabilizing wild-type neurofibromin through the dimerization interface; cryo-EM structure of neurofibromin was used to predict additional patient variants with similar dominant-negative mechanism, validated experimentally, providing a structural basis for genotype-phenotype correlations.","method":"Cryo-EM structure determination, patient variant protein expression and stability assays, co-immunoprecipitation to demonstrate dimerization-dependent dominant-negative effect, computational prediction of destabilizing variants with experimental validation","journal":"Proceedings of the National Academy of Sciences","confidence":"High","confidence_rationale":"Tier 1 / Strong — cryo-EM structure combined with mutagenesis, protein stability assays, and Co-IP mechanistic validation","pmids":["36689660"],"is_preprint":false}],"current_model":"Neurofibromin (NF1) is a GTPase-activating protein (GAP) that stimulates hydrolysis of RAS-GTP to RAS-GDP, thereby suppressing RAS/MAPK and PI3K/mTOR signaling; it forms a high-affinity homodimer (with some missense variants acting dominant-negatively through the dimer interface), interacts with CRMP2 to regulate nociceptive ion channels, regulates cAMP homeostasis in neurons via RAS→atypical PKC-ζ→GRK2→Gαs, controls Schwann cell proliferation through cyclin D1, modulates oligodendrocyte myelin integrity via Notch signaling, and requires both cell-autonomous loss (particularly in the Schwann cell/neural precursor lineage) and a haploinsufficient tumor microenvironment (including mast cells and bone marrow–derived cells signaling through c-kit and GM-CSF) for neurofibroma formation."},"narrative":{"mechanistic_narrative":"Neurofibromin (NF1) is a tumor-suppressor GTPase-activating protein whose central activity is to accelerate hydrolysis of RAS-GTP, thereby restraining downstream RAS effector cascades that govern cell proliferation, differentiation, and survival [PMID:9003501, PMID:15467460]. GTPase-activating activity is encoded by the GAP-related domain (exons 20–27a), where the R1391S substitution reduces catalytic activity ~300-fold [PMID:9003501]. Despite sharing in vitro GTPase-activating properties with p120-GAP, neurofibromin exerts distinct biological effects on RAS-driven transcription in cells [PMID:8455625]. Full-length neurofibromin functions as a high-affinity dimer, and the N- and C-terminal halves reconstitute dimer-like, GTPase-active structures when co-expressed [PMID:31836666]; patient variants clustered at the dimerization interface (codons 844–848 and others predicted from the cryo-EM structure) destabilize and dominantly inactivate wild-type protein, providing a structural basis for genotype–phenotype correlation [PMID:36689660]. Through control of RAS, neurofibromin loss deregulates both ERK/MAPK and PI3K/mTOR arms: it antagonizes cAMP accumulation and cyclin D1 to limit Schwann cell proliferation [PMID:11160381], suppresses BRAF-induced senescence via combined PI3K and ERK deregulation [PMID:23171796], and gates RAS-ERK attenuation downstream of mutant EGFR to set drug sensitivity in lung cancer [PMID:24535670]. In the nervous system, neurofibromin couples RAS to cAMP homeostasis through an atypical PKC-ζ→GRK2→Gαs route independent of MEK/AKT [PMID:25070947], restrains MAPK/PAK1 signaling underlying GABAergic and synaptic deficits [PMID:25242307], maintains oligodendrocyte myelin through suppression of Notch [PMID:28423318], and regulates nociceptive ion channels by sequestering CRMP2 away from syntaxin 1A and CaV2.2 [PMID:29655575]. Neurofibroma genesis requires cell-autonomous NF1 loss in the Schwann cell/neural-precursor lineage together with a haploinsufficient microenvironment, in which mast cells signaling through c-kit and bone marrow–derived cells acting via GM-CSF are essential contributors [PMID:11988578, PMID:18984156, PMID:10678181]. Germline NF1 loss in this disease also drives optic glioma through neuronal-activity–dependent NLGN3 shedding [PMID:34040258]. NF1 is the gene underlying neurofibromatosis type 1, in which distinct germline mutations confer distinct cell-autonomous and stromal tumor phenotypes [PMID:26908603].","teleology":[{"year":1993,"claim":"Established that neurofibromin, although a RAS-GAP, produces biological effects distinct from the canonical p120-GAP, implying a dedicated regulatory role rather than redundancy.","evidence":"Microinjection of purified type I NF1 vs. GAP into fibroblasts with AP-1 reporter and DNA-synthesis readouts","pmids":["8455625"],"confidence":"Medium","gaps":["Did not map the domain responsible","Single lab, indirect readouts of RAS output"]},{"year":1995,"claim":"Localized and quantified the catalytic GAP function to the GRD and demonstrated that a single missense mutation cripples activity, linking enzymatic loss to disease-associated variants.","evidence":"Site-directed mutagenesis (R1391S), in vitro expression, and direct GAP activity assay","pmids":["9003501"],"confidence":"High","gaps":["Does not address full-length regulation outside the GRD","No structural mechanism for the activity loss"]},{"year":1995,"claim":"Revealed isoform-specific and developmentally regulated forms of neurofibromin (type 1 vs type 2, exon 23a) with differing microtubule association, indicating non-GAP functional diversification.","evidence":"Northern/Western blot, in situ hybridization, and microtubule co-fractionation across tissues and mouse embryos","pmids":["7794799","7568895"],"confidence":"Medium","gaps":["Functional consequence of microtubule binding undefined","No mechanism linking isoform to RAS activity"]},{"year":2000,"claim":"Defined GM-CSF signaling as a required driver of Nf1-deficient myeloproliferation, establishing cytokine dependence of hematopoietic NF1 phenotypes.","evidence":"Nf1;Gmcsf double-knockout intercross with adoptive transfer and colony assays","pmids":["10678181"],"confidence":"High","gaps":["Did not connect to solid-tumor microenvironment","Mechanism of GM-CSF hypersensitivity at the receptor level not resolved"]},{"year":2001,"claim":"Placed cyclin D1 and cAMP downstream of Nf1 in Schwann cell growth control, identifying a concrete cell-cycle effector of neurofibromin loss.","evidence":"Inducible cyclin D1 retroviral expression, cAMP and BrdU assays in Nf1-/- vs WT Schwann cells","pmids":["11160381"],"confidence":"High","gaps":["Link from RAS to cAMP not yet mechanistically defined","Restricted to Schwann cell lineage"]},{"year":2002,"claim":"Demonstrated that Schwann cell-autonomous NF1 loss plus a heterozygous microenvironment is the combination required for neurofibroma formation, defining a two-compartment tumor model.","evidence":"Krox20-Cre conditional Nf1 knockout on Nf1+/- background with tumor histology","pmids":["11988578"],"confidence":"High","gaps":["Identity of the contributing stromal cell type unknown","Microenvironmental signals not yet defined"]},{"year":2006,"claim":"Showed NF1 expression is subject to CTCF-dependent long-range interchromosomal regulation, adding a transcriptional control layer.","evidence":"3C, FISH, CTCF knockdown and ICR-deletion mouse with Wsb1/Nf1 expression analysis","pmids":["16614224"],"confidence":"Medium","gaps":["Relevance to human NF1 disease unestablished","Single-locus mechanism, magnitude of expression effect modest"]},{"year":2008,"claim":"Identified mast cells, c-kit signaling, and an EGFR-dependent nerve progenitor pool as the cellular and receptor mediators of the neurofibroma microenvironment and cell of origin.","evidence":"Bone marrow transplantation, c-kit intercross, imatinib, DhhCre conditional KO, sphere assays, and human EGFR+/P75+ cell xenografts","pmids":["18984156","19041782"],"confidence":"High","gaps":["Quantitative contribution of each compartment unclear","How NF1-null Schwann cells recruit mast cells not yet defined"]},{"year":2009,"claim":"Identified skin-derived precursors as the cell of origin for dermal neurofibromas, refining the lineage in which NF1 loss initiates tumors.","evidence":"P0-Cre conditional Nf1 loss in SKPs with lineage tracing and transplantation","pmids":["19427294"],"confidence":"Medium","gaps":["Microenvironmental signals defined only as 'additional'","Relation to plexiform neurofibroma origin not addressed"]},{"year":2010,"claim":"Connected NF1 loss to mTOR survival dependency in AML and defined the SCF/Kit ligand–PI3K axis by which Nf1-/- Schwann cells provoke mast cell degranulation.","evidence":"Ras-GTP pulldown, shRNA, rapamycin sensitivity in AML blasts; conditioned-medium degranulation with Nf1/PI3K intercrosses","pmids":["20505189","21037083"],"confidence":"Medium","gaps":["mTOR dependency tested ex vivo only","Whether SCF-PI3K loop is generalizable across tumor stages unclear"]},{"year":2011,"claim":"Showed that timing and Schwann cell subtype of NF1 loss dictate neurofibroma onset and size, and confirmed non-cell-autonomous lympho-hematopoietic expansion.","evidence":"Tamoxifen-inducible PlpCre;Nf1fl/fl with EGFP lineage tracing across perinatal vs adult induction","pmids":["21551249"],"confidence":"Medium","gaps":["Molecular basis of differing tumor kinetics unresolved","Why GFAP+ non-myelinating cells are exempt unknown"]},{"year":2012,"claim":"Established NF1 as a cooperating tumor suppressor in melanoma that prevents oncogene-induced senescence and sets BRAF-inhibitor sensitivity through dual PI3K/ERK control.","evidence":"BRAF+Nf1 mouse model, senescence and proliferation assays, pathway biochemistry, BRAF-inhibitor sensitivity in cell lines","pmids":["23171796"],"confidence":"High","gaps":["Relative weighting of PI3K vs ERK contribution unresolved","Does not address other sporadic cancer contexts"]},{"year":2013,"claim":"Extended neurofibromin function beyond tumor suppression into muscle energy metabolism and vascular neointima formation via Ras-Erk in macrophages.","evidence":"Muscle-specific Nf1 KO with metabolic/enzymatic assays; Nf1+/- carotid injury model with MEK-inhibitor rescue","pmids":["24163128","24211110"],"confidence":"Medium","gaps":["Direct RAS substrate link in muscle metabolism not shown","Cell-autonomous vs systemic metabolic effects not separated"]},{"year":2014,"claim":"Resolved neuron-specific and tumor-specific effector branches: a RAS→PKC-ζ→GRK2→Gαs cAMP route, a MAPK/PAK1 synaptic axis, and a RAS-MAPK→MAF→mTOR crosstalk in MPNST; also defined NF1 control of EGFR-driven RAS-ERK attenuation.","evidence":"iPSC neural progenitors and Nf1 mice (cAMP); Pak1 KO/inhibitor amygdala rescue; MAF/DEPTOR overexpression with RAD001; genome-wide siRNA screen with MEK-inhibitor rescue","pmids":["25070947","25242307","24509877","24535670"],"confidence":"High","gaps":["How a single GAP selects distinct effector branches across cell types unknown","MAF transcriptional targets only partially mapped"]},{"year":2016,"claim":"Demonstrated that the specific germline NF1 mutation, via differing residual protein levels, determines both cell-autonomous proliferation and stromal glioma phenotype.","evidence":"Patient-derived R681X vs G848R knock-in mice with optic nerve, microglia, and astrocyte readouts","pmids":["26908603"],"confidence":"High","gaps":["Mechanism linking residual neurofibromin level to microglial activation incomplete","Generalizability to other variants untested here"]},{"year":2017,"claim":"Identified Notch and Wnt/β-catenin as tissue-specific downstream effectors of neurofibromin in oligodendrocyte myelin maintenance and fracture repair.","evidence":"Oligodendrocyte-specific Nf1 KO with γ-secretase/MEK/NOS inhibitor rescue and patient tissue; Nf1-/- fracture model with β-catenin readouts and Nefopam rescue","pmids":["28423318","28254468"],"confidence":"High","gaps":["Direct biochemical link from RAS to Notch/β-catenin not established","Whether effects are GAP-dependent untested"]},{"year":2018,"claim":"Established a non-canonical neurofibromin function in pain signaling through CRMP2 sequestration controlling NaV1.7/CaV2.2 and CGRP release.","evidence":"Co-IP network, CRISPR Nf1 editing, electrophysiology, CGRP release, and CNRP1 peptide rescue with behavior","pmids":["29655575"],"confidence":"High","gaps":["Whether CRMP2 interaction is GAP-domain dependent unclear","Human translation of CNRP1 rescue not addressed"]},{"year":2019,"claim":"Determined that full-length neurofibromin is an obligate high-affinity dimer reconstitutable from N- and C-terminal halves, defining its quaternary structure and a route to GTPase activation.","evidence":"SEC-MALS, SAXS/SANS, AUC, negative-stain EM, in vitro GTPase assay, and fragment reconstitution in cells","pmids":["31836666"],"confidence":"High","gaps":["Atomic-resolution interface not yet defined at this stage","Regulatory role of dimerization in vivo unaddressed"]},{"year":2021,"claim":"Showed that NF1-driven optic glioma requires neuronal-activity–dependent NLGN3 shedding, defining an obligate non-cell-autonomous initiation mechanism.","evidence":"Nf1 OPG mouse model with light deprivation, Nlgn3 KO, and ADAM10 shedding-inhibitor rescue plus MRI tumor quantification","pmids":["34040258"],"confidence":"High","gaps":["Link from neurofibromin loss to NLGN3 shedding sensitization not fully mechanistic","Restricted to optic pathway gliomas"]},{"year":2023,"claim":"Provided a cryo-EM structural basis for dominant-negative NF1 variants that destabilize wild-type neurofibromin via the dimer interface, enabling variant prediction.","evidence":"Cryo-EM structure, codon 844–848 variant stability assays, Co-IP, and computational prediction with experimental validation","pmids":["36689660"],"confidence":"High","gaps":["Clinical penetrance of predicted variants not established","Functional consequence on RAS output in patient cells not measured"]},{"year":null,"claim":"How a single dimeric RAS-GAP selects among its distinct cell-type-specific effector branches (cAMP/PKC-ζ, Notch, β-catenin, CRMP2, MAF-mTOR) and how dimerization is dynamically regulated in vivo remain unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No unifying mechanism linking GAP activity to non-RAS effector engagement","Regulation of dimer assembly/disassembly in cells unknown","Whether non-GAP functions require dimerization untested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,1,30]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[7,18,21,22]},{"term_id":"GO:0140313","term_label":"molecular sequestering activity","supporting_discovery_ids":[28]},{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[2,3]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[2,3]},{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[2,3]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,18,22]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[8,10,14,18]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[12,13,26]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[21,23,28]}],"complexes":["neurofibromin homodimer"],"partners":["CRMP2","STX1A","CACNA2 (CAV2.2)"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P21359","full_name":"Neurofibromin","aliases":["Neurofibromatosis-related protein NF-1"],"length_aa":2839,"mass_kda":319.4,"function":"Stimulates the GTPase activity of Ras. NF1 shows greater affinity for Ras GAP, but lower specific activity. May be a regulator of Ras activity","subcellular_location":"Nucleus; Nucleus, nucleolus; Cell membrane","url":"https://www.uniprot.org/uniprotkb/P21359/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/NF1","classification":"Not Classified","n_dependent_lines":20,"n_total_lines":1208,"dependency_fraction":0.016556291390728478},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"MIF","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/NF1","total_profiled":1310},"omim":[{"mim_id":"619913","title":"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 103; DEE103","url":"https://www.omim.org/entry/619913"},{"mim_id":"619173","title":"CEROID LIPOFUSCINOSIS, NEURONAL, 15; CLN15","url":"https://www.omim.org/entry/619173"},{"mim_id":"619101","title":"MISMATCH REPAIR CANCER SYNDROME 4; MMRCS4","url":"https://www.omim.org/entry/619101"},{"mim_id":"619097","title":"MISMATCH REPAIR CANCER SYNDROME 3; MMRCS3","url":"https://www.omim.org/entry/619097"},{"mim_id":"619096","title":"MISMATCH REPAIR CANCER SYNDROME 2; MMRCS2","url":"https://www.omim.org/entry/619096"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"},{"location":"Nucleoplasm","reliability":"Additional"},{"location":"Microtubules","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/NF1"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P21359","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P21359","model_url":"https://alphafold.ebi.ac.uk/files/AF-P21359-5-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P21359-5-F1-predicted_aligned_error_v6.png","plddt_mean":87.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=NF1","jax_strain_url":"https://www.jax.org/strain/search?query=NF1"},"sequence":{"accession":"P21359","fasta_url":"https://rest.uniprot.org/uniprotkb/P21359.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P21359/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P21359"}},"corpus_meta":[{"pmid":"11988578","id":"PMC_11988578","title":"Neurofibromas in NF1: Schwann cell origin and role of tumor environment.","date":"2002","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/11988578","citation_count":475,"is_preprint":false},{"pmid":"16614224","id":"PMC_16614224","title":"CTCF mediates interchromosomal colocalization between Igf2/H19 and Wsb1/Nf1.","date":"2006","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/16614224","citation_count":378,"is_preprint":false},{"pmid":"10625171","id":"PMC_10625171","title":"NF1 gene and neurofibromatosis 1.","date":"2000","source":"American journal of epidemiology","url":"https://pubmed.ncbi.nlm.nih.gov/10625171","citation_count":303,"is_preprint":false},{"pmid":"18984156","id":"PMC_18984156","title":"Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow.","date":"2008","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/18984156","citation_count":274,"is_preprint":false},{"pmid":"28637487","id":"PMC_28637487","title":"The NF1 somatic mutational landscape in sporadic human cancers.","date":"2017","source":"Human genomics","url":"https://pubmed.ncbi.nlm.nih.gov/28637487","citation_count":248,"is_preprint":false},{"pmid":"8825042","id":"PMC_8825042","title":"Molecular genetics of neurofibromatosis type 1 (NF1).","date":"1996","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8825042","citation_count":240,"is_preprint":false},{"pmid":"23171796","id":"PMC_23171796","title":"Elucidating distinct roles for NF1 in melanomagenesis.","date":"2012","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/23171796","citation_count":199,"is_preprint":false},{"pmid":"7774960","id":"PMC_7774960","title":"Genomic organization of the neurofibromatosis 1 gene (NF1).","date":"1995","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/7774960","citation_count":185,"is_preprint":false},{"pmid":"34040258","id":"PMC_34040258","title":"NF1 mutation drives neuronal activity-dependent initiation of optic glioma.","date":"2021","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/34040258","citation_count":182,"is_preprint":false},{"pmid":"24535670","id":"PMC_24535670","title":"Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer.","date":"2014","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/24535670","citation_count":173,"is_preprint":false},{"pmid":"28067895","id":"PMC_28067895","title":"The NF1 gene in tumor syndromes and melanoma.","date":"2017","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/28067895","citation_count":162,"is_preprint":false},{"pmid":"23931823","id":"PMC_23931823","title":"Neurofibromatosis type 1 (NF1): diagnosis and management.","date":"2013","source":"Handbook of clinical neurology","url":"https://pubmed.ncbi.nlm.nih.gov/23931823","citation_count":158,"is_preprint":false},{"pmid":"25026295","id":"PMC_25026295","title":"The NF1 gene revisited - from bench to bedside.","date":"2014","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25026295","citation_count":144,"is_preprint":false},{"pmid":"19427294","id":"PMC_19427294","title":"Cell of origin and microenvironment contribution for NF1-associated dermal neurofibromas.","date":"2009","source":"Cell stem cell","url":"https://pubmed.ncbi.nlm.nih.gov/19427294","citation_count":140,"is_preprint":false},{"pmid":"12041525","id":"PMC_12041525","title":"Plexiform neurofibromas in NF1: toward biologic-based therapy.","date":"2002","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/12041525","citation_count":119,"is_preprint":false},{"pmid":"10678181","id":"PMC_10678181","title":"Nf1 and Gmcsf interact in myeloid leukemogenesis.","date":"2000","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/10678181","citation_count":118,"is_preprint":false},{"pmid":"22962301","id":"PMC_22962301","title":"Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma.","date":"2012","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22962301","citation_count":115,"is_preprint":false},{"pmid":"25242307","id":"PMC_25242307","title":"Social learning and amygdala disruptions in Nf1 mice are rescued by blocking p21-activated kinase.","date":"2014","source":"Nature neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/25242307","citation_count":110,"is_preprint":false},{"pmid":"28267273","id":"PMC_28267273","title":"NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics.","date":"2017","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28267273","citation_count":104,"is_preprint":false},{"pmid":"19142971","id":"PMC_19142971","title":"Germline and somatic NF1 mutations in sporadic and NF1-associated malignant peripheral nerve sheath tumours.","date":"2009","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/19142971","citation_count":100,"is_preprint":false},{"pmid":"9375928","id":"PMC_9375928","title":"Do NF1 gene deletions result in a characteristic phenotype?","date":"1997","source":"American journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9375928","citation_count":100,"is_preprint":false},{"pmid":"12403554","id":"PMC_12403554","title":"Genetics of neurofibromatosis 1 and the NF1 gene.","date":"2002","source":"Journal of child neurology","url":"https://pubmed.ncbi.nlm.nih.gov/12403554","citation_count":99,"is_preprint":false},{"pmid":"18803326","id":"PMC_18803326","title":"How does the Schwann cell lineage form tumors in NF1?","date":"2008","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/18803326","citation_count":97,"is_preprint":false},{"pmid":"17960768","id":"PMC_17960768","title":"Germline and somatic NF1 gene mutation spectrum in NF1-associated malignant peripheral nerve sheath tumors (MPNSTs).","date":"2008","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/17960768","citation_count":93,"is_preprint":false},{"pmid":"11160381","id":"PMC_11160381","title":"Schwann cell proliferative responses to cAMP and Nf1 are mediated by cyclin D1.","date":"2001","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/11160381","citation_count":93,"is_preprint":false},{"pmid":"26076063","id":"PMC_26076063","title":"NF1 Mutations Are Common in Desmoplastic Melanoma.","date":"2015","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26076063","citation_count":90,"is_preprint":false},{"pmid":"16941471","id":"PMC_16941471","title":"Comprehensive NF1 screening on cultured Schwann cells from neurofibromas.","date":"2006","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/16941471","citation_count":87,"is_preprint":false},{"pmid":"20345245","id":"PMC_20345245","title":"Molecular and cellular mechanisms of learning disabilities: a focus on NF1.","date":"2010","source":"Annual review of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/20345245","citation_count":86,"is_preprint":false},{"pmid":"27617404","id":"PMC_27617404","title":"Immortalization of human normal and NF1 neurofibroma Schwann cells.","date":"2016","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/27617404","citation_count":86,"is_preprint":false},{"pmid":"9003501","id":"PMC_9003501","title":"Mutational and functional analysis of the neurofibromatosis type 1 (NF1) gene.","date":"1997","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9003501","citation_count":83,"is_preprint":false},{"pmid":"21354044","id":"PMC_21354044","title":"A highly sensitive genetic protocol to detect NF1 mutations.","date":"2011","source":"The Journal of molecular diagnostics : JMD","url":"https://pubmed.ncbi.nlm.nih.gov/21354044","citation_count":82,"is_preprint":false},{"pmid":"22240541","id":"PMC_22240541","title":"Neoplasms associated with germline and somatic NF1 gene mutations.","date":"2012","source":"The oncologist","url":"https://pubmed.ncbi.nlm.nih.gov/22240541","citation_count":80,"is_preprint":false},{"pmid":"22125493","id":"PMC_22125493","title":"The NF1 gene contains hotspots for L1 endonuclease-dependent de novo insertion.","date":"2011","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22125493","citation_count":80,"is_preprint":false},{"pmid":"7749326","id":"PMC_7749326","title":"Ras signaling and NF1.","date":"1995","source":"Current opinion in genetics & development","url":"https://pubmed.ncbi.nlm.nih.gov/7749326","citation_count":76,"is_preprint":false},{"pmid":"7794799","id":"PMC_7794799","title":"Expression of the neurofibromatosis 1 (NF1) isoforms in developing and adult rat tissues.","date":"1995","source":"Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/7794799","citation_count":76,"is_preprint":false},{"pmid":"25070947","id":"PMC_25070947","title":"Neuronal NF1/RAS regulation of cyclic AMP requires atypical PKC activation.","date":"2014","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25070947","citation_count":74,"is_preprint":false},{"pmid":"10459349","id":"PMC_10459349","title":"Allelic loss of the NF1 gene in NF1-associated plexiform neurofibromas.","date":"1999","source":"Cancer genetics and cytogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/10459349","citation_count":73,"is_preprint":false},{"pmid":"29559732","id":"PMC_29559732","title":"NF1 mutations in conjunctival melanoma.","date":"2018","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29559732","citation_count":72,"is_preprint":false},{"pmid":"9643287","id":"PMC_9643287","title":"Constitutional and mosaic large NF1 gene deletions in neurofibromatosis type 1.","date":"1998","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9643287","citation_count":72,"is_preprint":false},{"pmid":"7981724","id":"PMC_7981724","title":"Molecular basis of neurofibromatosis type 1 (NF1): mutation analysis and polymorphisms in the NF1 gene.","date":"1994","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/7981724","citation_count":71,"is_preprint":false},{"pmid":"26861459","id":"PMC_26861459","title":"Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer.","date":"2016","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/26861459","citation_count":69,"is_preprint":false},{"pmid":"26908603","id":"PMC_26908603","title":"NF1 germline mutation differentially dictates optic glioma formation and growth in neurofibromatosis-1.","date":"2016","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26908603","citation_count":67,"is_preprint":false},{"pmid":"27322474","id":"PMC_27322474","title":"Comprehensive RNA Analysis of the NF1 Gene in Classically Affected NF1 Affected Individuals Meeting NIH Criteria has High Sensitivity and Mutation Negative Testing is Reassuring in Isolated Cases With Pigmentary Features Only.","date":"2016","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/27322474","citation_count":65,"is_preprint":false},{"pmid":"20505189","id":"PMC_20505189","title":"NF1 inactivation in adult acute myelogenous leukemia.","date":"2010","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/20505189","citation_count":62,"is_preprint":false},{"pmid":"21551249","id":"PMC_21551249","title":"Perinatal or adult Nf1 inactivation using tamoxifen-inducible PlpCre each cause neurofibroma formation.","date":"2011","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/21551249","citation_count":57,"is_preprint":false},{"pmid":"18248783","id":"PMC_18248783","title":"Recent insights into bone development, homeostasis, and repair in type 1 neurofibromatosis (NF1).","date":"2007","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/18248783","citation_count":57,"is_preprint":false},{"pmid":"34928431","id":"PMC_34928431","title":"Challenges in the diagnosis of neurofibromatosis type 1 (NF1) in young children facilitated by means of revised diagnostic criteria including genetic testing for pathogenic NF1 gene variants.","date":"2021","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34928431","citation_count":56,"is_preprint":false},{"pmid":"30182054","id":"PMC_30182054","title":"NF1 deficiency correlates with estrogen receptor signaling and diminished survival in breast cancer.","date":"2018","source":"NPJ breast cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30182054","citation_count":54,"is_preprint":false},{"pmid":"26925841","id":"PMC_26925841","title":"Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression.","date":"2016","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26925841","citation_count":54,"is_preprint":false},{"pmid":"18592002","id":"PMC_18592002","title":"RAS signaling in colorectal carcinomas through alteration of RAS, RAF, NF1, and/or RASSF1A.","date":"2008","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/18592002","citation_count":51,"is_preprint":false},{"pmid":"19221814","id":"PMC_19221814","title":"The spectrum of somatic and germline NF1 mutations in NF1 patients with spinal neurofibromas.","date":"2009","source":"Neurogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/19221814","citation_count":51,"is_preprint":false},{"pmid":"16288202","id":"PMC_16288202","title":"Nf1 haploinsufficiency augments angiogenesis.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16288202","citation_count":47,"is_preprint":false},{"pmid":"15467460","id":"PMC_15467460","title":"Ras/Raf/ERK signalling and NF1.","date":"2004","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/15467460","citation_count":46,"is_preprint":false},{"pmid":"30479396","id":"PMC_30479396","title":"NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30479396","citation_count":46,"is_preprint":false},{"pmid":"18481270","id":"PMC_18481270","title":"The role of steroid hormones in the NF1 phenotype: focus on pregnancy.","date":"2008","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/18481270","citation_count":43,"is_preprint":false},{"pmid":"9300663","id":"PMC_9300663","title":"RNA processing and clinical variability in neurofibromatosis type I (NF1).","date":"1997","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9300663","citation_count":42,"is_preprint":false},{"pmid":"31776437","id":"PMC_31776437","title":"Phenotype categorization of neurofibromatosis type I and correlation to NF1 mutation types.","date":"2019","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31776437","citation_count":41,"is_preprint":false},{"pmid":"24163128","id":"PMC_24163128","title":"NF1 is a critical regulator of muscle development and metabolism.","date":"2013","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24163128","citation_count":41,"is_preprint":false},{"pmid":"1505963","id":"PMC_1505963","title":"NF1-related locus on chromosome 15.","date":"1992","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/1505963","citation_count":41,"is_preprint":false},{"pmid":"28423318","id":"PMC_28423318","title":"Oligodendrocyte Nf1 Controls Aberrant Notch Activation and Regulates Myelin Structure and Behavior.","date":"2017","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/28423318","citation_count":40,"is_preprint":false},{"pmid":"19041782","id":"PMC_19041782","title":"Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor that confers neurofibroma tumorigenic potential.","date":"2008","source":"Cell stem cell","url":"https://pubmed.ncbi.nlm.nih.gov/19041782","citation_count":40,"is_preprint":false},{"pmid":"31836666","id":"PMC_31836666","title":"Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.","date":"2019","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31836666","citation_count":39,"is_preprint":false},{"pmid":"25062113","id":"PMC_25062113","title":"Neurofibromatosis type 1 (NF1) and associated tumors.","date":"2014","source":"Klinische Padiatrie","url":"https://pubmed.ncbi.nlm.nih.gov/25062113","citation_count":38,"is_preprint":false},{"pmid":"27473134","id":"PMC_27473134","title":"GABA deficiency in NF1: A multimodal [11C]-flumazenil and spectroscopy study.","date":"2016","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/27473134","citation_count":37,"is_preprint":false},{"pmid":"27622733","id":"PMC_27622733","title":"Neurofibromatosis type 1 (NF1) gene: Beyond café au lait spots and dermal neurofibromas.","date":"2016","source":"Experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/27622733","citation_count":36,"is_preprint":false},{"pmid":"2506682","id":"PMC_2506682","title":"Progress towards identifying the neurofibromatosis (NF1) gene.","date":"1989","source":"Trends in genetics : TIG","url":"https://pubmed.ncbi.nlm.nih.gov/2506682","citation_count":36,"is_preprint":false},{"pmid":"31993017","id":"PMC_31993017","title":"Can the Cognitive Phenotype in Neurofibromatosis Type 1 (NF1) Be Explained by Neuroimaging? A Review.","date":"2020","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/31993017","citation_count":34,"is_preprint":false},{"pmid":"24509877","id":"PMC_24509877","title":"MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.","date":"2014","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/24509877","citation_count":33,"is_preprint":false},{"pmid":"19615906","id":"PMC_19615906","title":"Neurofibroma development in NF1--insights into tumour initiation.","date":"2009","source":"Trends in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/19615906","citation_count":33,"is_preprint":false},{"pmid":"32642730","id":"PMC_32642730","title":"After Nf1 loss in Schwann cells, inflammation drives neurofibroma formation.","date":"2019","source":"Neuro-oncology advances","url":"https://pubmed.ncbi.nlm.nih.gov/32642730","citation_count":32,"is_preprint":false},{"pmid":"12552569","id":"PMC_12552569","title":"NF1 gene analysis based on DHPLC.","date":"2003","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/12552569","citation_count":32,"is_preprint":false},{"pmid":"31127187","id":"PMC_31127187","title":"Feasibility of using NF1-GRD and AAV for gene replacement therapy in NF1-associated tumors.","date":"2019","source":"Gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/31127187","citation_count":31,"is_preprint":false},{"pmid":"21037083","id":"PMC_21037083","title":"Nf1-/- Schwann cell-conditioned medium modulates mast cell degranulation by c-Kit-mediated hyperactivation of phosphatidylinositol 3-kinase.","date":"2010","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21037083","citation_count":31,"is_preprint":false},{"pmid":"8455625","id":"PMC_8455625","title":"Differential regulation of cellular activities by GTPase-activating protein and NF1.","date":"1993","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8455625","citation_count":31,"is_preprint":false},{"pmid":"10534774","id":"PMC_10534774","title":"Germline mutations in NF1 patients with malignancies.","date":"1999","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/10534774","citation_count":31,"is_preprint":false},{"pmid":"29655575","id":"PMC_29655575","title":"CRMP2-Neurofibromin Interface Drives NF1-related Pain.","date":"2018","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/29655575","citation_count":30,"is_preprint":false},{"pmid":"26190195","id":"PMC_26190195","title":"Clinicopathologic implications of NF1 gene alterations in diffuse gliomas.","date":"2015","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26190195","citation_count":30,"is_preprint":false},{"pmid":"34199217","id":"PMC_34199217","title":"Severe Phenotype in Patients with Large Deletions of NF1.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34199217","citation_count":30,"is_preprint":false},{"pmid":"34535841","id":"PMC_34535841","title":"Classification of NF1 microdeletions and its importance for establishing genotype/phenotype correlations in patients with NF1 microdeletions.","date":"2021","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34535841","citation_count":29,"is_preprint":false},{"pmid":"19845691","id":"PMC_19845691","title":"Noonan syndrome and neurofibromatosis type I in a family with a novel mutation in NF1.","date":"2009","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19845691","citation_count":29,"is_preprint":false},{"pmid":"15233998","id":"PMC_15233998","title":"Genomic organization and evolution of the NF1 microdeletion region.","date":"2004","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/15233998","citation_count":29,"is_preprint":false},{"pmid":"30843352","id":"PMC_30843352","title":"The Arg1038Gly missense variant in the NF1 gene causes a mild phenotype without neurofibromas.","date":"2019","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30843352","citation_count":28,"is_preprint":false},{"pmid":"33061844","id":"PMC_33061844","title":"Advancement in research and therapy of NF1 mutant malignant tumors.","date":"2020","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/33061844","citation_count":26,"is_preprint":false},{"pmid":"30226831","id":"PMC_30226831","title":"Chromatin regulator Asxl1 loss and Nf1 haploinsufficiency cooperate to accelerate myeloid malignancy.","date":"2018","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/30226831","citation_count":26,"is_preprint":false},{"pmid":"24211110","id":"PMC_24211110","title":"Ras-Mek-Erk signaling regulates Nf1 heterozygous neointima formation.","date":"2013","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/24211110","citation_count":26,"is_preprint":false},{"pmid":"8820972","id":"PMC_8820972","title":"Increased expression of the neurofibromatosis 1 (NF1) gene product, neurofibromin, in astrocytes in response to cerebral ischemia.","date":"1996","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/8820972","citation_count":26,"is_preprint":false},{"pmid":"21931722","id":"PMC_21931722","title":"The probable cell of origin of NF1- and PDGF-driven glioblastomas.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21931722","citation_count":25,"is_preprint":false},{"pmid":"37747491","id":"PMC_37747491","title":"NF1 alterations in cancers: therapeutic implications in precision medicine.","date":"2023","source":"Expert opinion on investigational drugs","url":"https://pubmed.ncbi.nlm.nih.gov/37747491","citation_count":24,"is_preprint":false},{"pmid":"36689660","id":"PMC_36689660","title":"Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.","date":"2023","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/36689660","citation_count":24,"is_preprint":false},{"pmid":"32533297","id":"PMC_32533297","title":"Clinical characterization of children and adolescents with NF1 microdeletions.","date":"2020","source":"Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery","url":"https://pubmed.ncbi.nlm.nih.gov/32533297","citation_count":24,"is_preprint":false},{"pmid":"28392281","id":"PMC_28392281","title":"Human stem cell modeling in neurofibromatosis type 1 (NF1).","date":"2017","source":"Experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/28392281","citation_count":23,"is_preprint":false},{"pmid":"33921292","id":"PMC_33921292","title":"Non-Oncological Neuroradiological Manifestations in NF1 and Their Clinical Implications.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/33921292","citation_count":23,"is_preprint":false},{"pmid":"26189818","id":"PMC_26189818","title":"Decoding NF1 Intragenic Copy-Number Variations.","date":"2015","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26189818","citation_count":23,"is_preprint":false},{"pmid":"7568895","id":"PMC_7568895","title":"Expression of the neurofibromatosis type 1 (NF1) gene during mouse embryonic development.","date":"1995","source":"Progress in brain research","url":"https://pubmed.ncbi.nlm.nih.gov/7568895","citation_count":22,"is_preprint":false},{"pmid":"29522274","id":"PMC_29522274","title":"Neurofibromin (NF1) genetic variant structure-function analyses using a full-length mouse cDNA.","date":"2018","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/29522274","citation_count":21,"is_preprint":false},{"pmid":"34782607","id":"PMC_34782607","title":"Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq.","date":"2021","source":"NPJ genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34782607","citation_count":21,"is_preprint":false},{"pmid":"16937374","id":"PMC_16937374","title":"NF1 mutation rather than individual genetic variability is the main determinant of the NF1-transcriptional profile of mutations affecting splicing.","date":"2006","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/16937374","citation_count":21,"is_preprint":false},{"pmid":"8892969","id":"PMC_8892969","title":"NF1 mRNA isoform expression in PC12 cells: modulation by extrinsic factors.","date":"1996","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/8892969","citation_count":20,"is_preprint":false},{"pmid":"28254468","id":"PMC_28254468","title":"Pharmacologically targeting beta-catenin for NF1 associated deficiencies in fracture repair.","date":"2017","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/28254468","citation_count":20,"is_preprint":false},{"pmid":"12403553","id":"PMC_12403553","title":"NF1 mutations and molecular testing.","date":"2002","source":"Journal of child neurology","url":"https://pubmed.ncbi.nlm.nih.gov/12403553","citation_count":19,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":45776,"output_tokens":8833,"usd":0.134911,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18821,"output_tokens":6145,"usd":0.123865,"stage2_stop_reason":"end_turn"},"total_usd":0.258776,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1993,\n      \"finding\": \"Full-length type I NF1 (neurofibromin) coinjected with wild-type Ras abolished Ras-induced AP-1 reporter gene expression in fibroblasts, whereas type II GAP did not; serum-stimulated DNA synthesis was reduced by type I GAP but not by type I NF1, demonstrating that NF1 and GAP have distinct in vivo biological activities despite similar in vitro GTPase-activating properties toward Ras.\",\n      \"method\": \"Microinjection of purified proteins into fibroblasts, AP-1-controlled reporter gene assay, DNA synthesis measurement\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — direct in vitro/cell-injection assay with functional readout, single lab, single study\",\n      \"pmids\": [\"8455625\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"The GAP-related domain (GRD) of neurofibromin encoded by exons 20–27a is required for GTPase-activating activity toward Ras; the missense mutation R1391S in the GRD reduces GAP activity approximately 300-fold compared to wild-type NF1 GRD, as measured by in vitro GAP assay after site-directed mutagenesis and expression.\",\n      \"method\": \"Site-directed mutagenesis, in vitro expression, GAP activity assay\",\n      \"journal\": \"Human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with mutagenesis and direct enzymatic assay; finding consistent with multiple studies\",\n      \"pmids\": [\"9003501\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"NF1 type 1 and type 2 isoforms (differing by the 21-amino-acid exon 23a insertion) are differentially expressed: type 1 predominates in CNS neurons and is associated with microtubule binding, while type 2 predominates in glial cells and during early embryogenesis; type 2 neurofibromin does not associate with brain cytoplasmic microtubules in the same fashion as type 1, suggesting isoform-specific functional differences.\",\n      \"method\": \"Northern blot, in situ hybridization, Western blot analysis of tissue fractions, microtubule co-fractionation assay\",\n      \"journal\": \"Cell growth & differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (Northern, ISH, Western, fractionation) in single lab\",\n      \"pmids\": [\"7794799\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"During mouse embryogenesis, type 2 NF1 mRNA predominates before embryonic day 10, after which type 1 NF1 mRNA becomes predominant; type 2 neurofibromin is not associated with cytoplasmic microtubules in brain in the same fashion as type 1, suggesting the developmental isoform switch has functional consequences for microtubule interaction.\",\n      \"method\": \"Northern blot, Western blot, cytoplasmic microtubule co-fractionation in mouse brain\",\n      \"journal\": \"Progress in brain research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple methods (Northern, Western, fractionation), single lab\",\n      \"pmids\": [\"7568895\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Neurofibromin expression is upregulated in reactive astrocytes in response to cerebral ischemia (both focal and global models in rats), co-incident with GFAP upregulation, indicating a role for neurofibromin in injury-induced growth regulatory pathways in astrocytes.\",\n      \"method\": \"Immunohistochemistry in rat focal and global ischemia models, Western blot\",\n      \"journal\": \"Journal of neuroscience research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, single method (IHC/Western), no direct functional manipulation of NF1\",\n      \"pmids\": [\"8820972\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"The NF1 alternative splicing of exons 23a/23b in the GRD region can be modulated by extrinsic factors in PC12 cells: nerve growth factor and dexamethasone increase the type I isoform concurrent with decreased proliferation; cycloheximide treatment reveals an additional transcript (type III). Dexamethasone effect is RNA-synthesis-dependent.\",\n      \"method\": \"RT-PCR isoform analysis in PC12 cells with pharmacological treatments (NGF, dexamethasone, cycloheximide), actinomycin D block\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, descriptive RT-PCR without direct functional validation of isoform-specific effects\",\n      \"pmids\": [\"8892969\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"GM-CSF plays a central role in establishing and maintaining the myeloproliferative disorder (MPD) driven by Nf1 deficiency: hematopoietic cells doubly deficient in Nf1 and Gmcsf fail to induce MPD in recipients, but remain hypersensitive to exogenous GM-CSF, demonstrating that Nf1-deficient myeloid cells require GM-CSF signaling for their excessive proliferation in vivo.\",\n      \"method\": \"Genetic intercross of Nf1 and Gmcsf knockout mice, adoptive transfer of fetal liver hematopoietic cells, methylcellulose colony assay, exogenous GM-CSF challenge\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with double-knockout rescue, adoptive transfer, multiple orthogonal approaches, in vivo and in vitro readouts\",\n      \"pmids\": [\"10678181\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"In Schwann cells, Nf1 tumor suppressor function antagonizes the accumulation of cAMP and the expression of cyclin D1: ectopic expression of cyclin D1 using an inducible retroviral vector bypasses the G1 phase requirement for cAMP in Schwann cell proliferation, and loss of Nf1 increases cAMP and cyclin D1 levels, placing cyclin D1 as a downstream effector of Nf1-dependent growth control.\",\n      \"method\": \"Inducible retroviral expression of cyclin D1 in Schwann cells, cAMP measurement, cyclin D1 immunoblot, BrdU proliferation assay, Nf1-/- vs. wild-type Schwann cell comparison\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple methods (retroviral overexpression, genetic KO cells, biochemical measurements), direct epistasis established in primary cells\",\n      \"pmids\": [\"11160381\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Loss of NF1 specifically in the Schwann cell lineage (using cre/lox conditional allele driven by Schwann cell-specific Krox20/Egr2-Cre) is sufficient to generate neurofibromas; however, complete tumorigenesis also requires NF1 heterozygosity in the surrounding non-neoplastic microenvironment.\",\n      \"method\": \"Conditional Schwann cell-specific Nf1 knockout mouse (cre/lox), tumor histology, genetic epistasis with germline Nf1+/- background\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean conditional KO with defined cell-type specificity, complemented by haploinsufficiency epistasis experiment, replicated by subsequent labs\",\n      \"pmids\": [\"11988578\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CTCF mediates interchromosomal colocalization between the Igf2/H19 imprinting control region on chromosome 7 and the Wsb1/Nf1 locus on chromosome 11; deletion of the maternal ICR or omission of CTCF abrogates this association and alters Wsb1/Nf1 gene expression, establishing CTCF-dependent long-range transcriptional regulation of NF1.\",\n      \"method\": \"Modified chromosome conformation capture (3C), fluorescence in situ hybridization (FISH), CTCF knockdown, ICR deletion mouse model, RT-PCR of Wsb1/Nf1 expression\",\n      \"journal\": \"Science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — 3C and FISH with functional readout (gene expression), single lab, two orthogonal methods\",\n      \"pmids\": [\"16614224\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Nf1 heterozygosity in bone marrow-derived cells (specifically mast cells) in the tumor microenvironment is sufficient to allow neurofibroma progression when combined with Schwann cell Nf1 deficiency; genetic or pharmacologic attenuation of c-kit signaling in Nf1+/- hematopoietic cells diminishes neurofibroma initiation and progression, identifying mast cells and c-kit signaling as critical mediators.\",\n      \"method\": \"Bone marrow transplantation between Nf1 genotypes, conditional Schwann cell Nf1 KO (DhhCre), c-kit genetic intercross, imatinib pharmacological inhibition, tumor histology and quantification\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic rescue/epistasis with bone marrow transfer, pharmacological validation, multiple orthogonal approaches\",\n      \"pmids\": [\"18984156\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Ras/Raf/ERK signaling drives de-differentiation of myelinating Schwann cells, a process relevant to NF1-associated tumor formation; Schwann cells lacking Nf1 show elevated Ras-ERK activity that promotes de-differentiation.\",\n      \"method\": \"Conditional NF1 knockout Schwann cells, Ras/ERK pathway assays, Schwann cell de-differentiation markers\",\n      \"journal\": \"Cell cycle\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — review/commentary-type abstract with limited primary experimental detail provided\",\n      \"pmids\": [\"15467460\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Skin-derived precursor (SKP) stem/progenitor cells residing in the dermis serve as the cell of origin for dermal neurofibromas upon loss of Nf1; non-neoplastic cells in the tumor microenvironment provide additional signals essential for neurofibromagenesis.\",\n      \"method\": \"Conditional Nf1 loss in SKPs (P0-Cre), tumor histology, lineage tracing, co-culture/transplantation experiments\",\n      \"journal\": \"Cell stem cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with lineage tracing and transplantation, single lab, multiple methods\",\n      \"pmids\": [\"19427294\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Nf1 loss of function amplifies an EGFR-dependent peripheral nerve progenitor pool in embryonic dorsal root ganglia; these Nf1-null progenitors are hypersensitive to growth factors, confer tumorigenesis in vivo, and human NF1 neurofibromas contain EGFR+/P75+ cells that form spheres and give rise to neurofibroma-like lesions in nude mice.\",\n      \"method\": \"In vitro sphere-formation assay, genetic (DhhCre;Nf1fl/fl) and pharmacologic (EGFR inhibition) tools, prospective FACS isolation of human EGFR+/P75+ cells, xenograft assay in nude mice\",\n      \"journal\": \"Cell stem cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (genetic KO, pharmacological, xenograft, human primary cells), single lab with comprehensive experimental design\",\n      \"pmids\": [\"19041782\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"NF1 null states in adult AML are associated with increased Ras-bound GTP; shRNA-mediated NF1 suppression in primary AML blasts with wild-type NF1 facilitates colony formation; NF1-null AML blasts show selective sensitivity to rapamycin-induced apoptosis, identifying mTOR as a survival dependency in NF1-null AML.\",\n      \"method\": \"SNP array, NF1 sequencing, Ras-GTP pulldown assay, shRNA knockdown, colony formation in methylcellulose, rapamycin treatment of primary blasts and CD34+/CD38- cells\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Ras-GTP biochemical assay plus shRNA functional validation plus ex vivo pharmacological, single lab\",\n      \"pmids\": [\"20505189\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"In Nf1+/- mice, disruption of Ras regulation of inhibitory (GABAergic) neuronal networks is critical to the etiology of cognitive deficits; Nf1 haploinsufficiency increases GABA neurotransmitter pathway activity and MAPK signaling in neurons, and these phenotypes are rescued by pharmacological or genetic reduction of MAPK pathway activity.\",\n      \"method\": \"Nf1+/- mouse behavioral assays, electrophysiology, MAPK pathway inhibitors (lovastatin), genetic epistasis\",\n      \"journal\": \"Annual review of neuroscience\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — review article summarizing prior findings; primary experimental data not described in this abstract\",\n      \"pmids\": [\"20345245\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Nf1-/- Schwann cell-conditioned medium promotes increased degranulation of Nf1+/- mast cells compared with wild-type mast cells via secretion of Kit ligand (SCF); this effect is mediated by hyperactivation of the p21Ras-PI3K pathway, as demonstrated by genetic intercross and pharmacological inhibition.\",\n      \"method\": \"Schwann cell conditioned medium treatment of mast cells, degranulation assay, genetic Nf1/PI3K intercrosses, pharmacological PI3K inhibition, in vitro and in vivo measurements\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and pharmacological approaches combined with functional cell assays, single lab\",\n      \"pmids\": [\"21037083\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Perinatal or adult induction of Nf1 loss in the Schwann cell lineage using tamoxifen-inducible PlpCre each cause neurofibroma formation; perinatal loss yields small neurofibromas late in life while adult loss causes large neurofibromas with earlier onset; EGFP reporter identifies that Nf1 loss in S100β+ myelinating and p75+ peripheral nerve Schwann cells but not GFAP+ non-myelinating Schwann cells contributes to tumors. A non-cell-autonomous effect of Nf1-deleted microenvironment on lympho-hematopoietic expansion was also identified.\",\n      \"method\": \"Tamoxifen-inducible PlpCre;Nf1fl/fl conditional knockout, conditional EGFP reporter lineage tracing, histological analysis, tumor timing/size quantification\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional inducible KO with lineage tracing, single lab, two timing conditions tested\",\n      \"pmids\": [\"21551249\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"NF1 mutations cooperate with BRAF mutations in melanomagenesis by preventing oncogene-induced senescence (OIS); Nf1 mutations suppress Braf-induced senescence in a genetically engineered mouse model and function by deregulating both PI3K and ERK pathways; NF1 ablation decreases sensitivity of melanoma cell lines to BRAF inhibitors.\",\n      \"method\": \"Genetically engineered mouse model (BRAF+Nf1 mutations), senescence assays (SA-β-gal), proliferation assays, PI3K/ERK pathway biochemistry, BRAF inhibitor sensitivity assays in cell lines\",\n      \"journal\": \"Cancer discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mouse genetic model plus mechanistic pathway analysis plus human cell line validation, multiple orthogonal methods\",\n      \"pmids\": [\"23171796\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Nf1 deficiency in muscle results in neonatal lethality in muscle-specific knockouts; the limb-specific Nf1Prx1-/- conditional knockout shows 10-fold increased muscle triglyceride content, increased activities of oxidative metabolism enzymes, elevated fatty acid synthase and leptin expression, and decreased fatty acid transporters, establishing NF1 as essential for normal muscle energy metabolism.\",\n      \"method\": \"Conditional muscle-specific Nf1 knockout mice (Nf1muscle-/- and Nf1Prx1-/-), electron microscopy, Oil Red O staining, enzyme activity assays, Western blot\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple tissue-specific conditional KO models with orthogonal biochemical assays, single lab\",\n      \"pmids\": [\"24163128\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Ras-Erk signaling in neurofibromin-deficient macrophages is the aberrant pathway responsible for enhanced neointima formation in NF1: Nf1+/- macrophages show enhanced Erk signaling in vitro; in vivo Nf1+/- mice show increased intimal proliferation after carotid artery injury; MEK inhibitor PD0325901 reduces Nf1+/- neointima formation to wild-type levels without affecting PI3K signaling.\",\n      \"method\": \"Carotid artery injury model in Nf1+/- mice, ERK and PI3K phosphorylation assays, macrophage migration assays, PD0325901 pharmacological inhibition, morphometric neointima analysis\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo pharmacological rescue with pathway biochemistry, single lab, multiple readouts\",\n      \"pmids\": [\"24211110\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Neurofibromin regulation of cAMP in neurons requires RAS activation followed by atypical PKC-zeta activation, which drives GRK2-mediated Gαs inactivation; this was established using iPSC-derived NF1 patient neural progenitors and Nf1 genetically engineered mice, demonstrating that MEK/AKT pathways are not involved in the RAS→cAMP connection in neurons.\",\n      \"method\": \"iPSC-derived neural progenitors from NF1 patients, Nf1 genetically engineered mice, cAMP measurement, PKC-zeta inhibition, GRK2 knockdown, MEK/AKT inhibitors\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — human iPSC model plus mouse model with pharmacological dissection of pathway; multiple orthogonal approaches in single comprehensive study\",\n      \"pmids\": [\"25070947\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Reduced NF1/neurofibromin expression impairs RAS-ERK signal attenuation downstream of mutant EGFR; erlotinib fails to fully inhibit RAS-ERK signaling when neurofibromin levels are reduced; MEK inhibitor treatment restores erlotinib sensitivity in neurofibromin-deficient lung cancer cells.\",\n      \"method\": \"Genome-wide siRNA screen in human lung cancer cells, Western blot (neurofibromin, pERK), MEK inhibitor combination treatment, murine EGFR-driven lung adenocarcinoma model\",\n      \"journal\": \"Cancer discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genome-wide siRNA screen validated with biochemical pathway analysis and pharmacological rescue, mouse model confirmation\",\n      \"pmids\": [\"24535670\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Nf1+/- mice show a selective social learning deficit associated with greater activation of the MAPK pathway in amygdala and frontal cortex neurons; Nf1+/- amygdala exhibits aberrant glutamate and GABA neurotransmission, deficits in LTP, and specific disruptions in ADAM22 and HSP70 protein expression; all amygdala disruptions and social behavior deficits are rescued by deletion of Pak1 or pharmacological Pak1 blockade in the amygdala.\",\n      \"method\": \"Nf1+/- mouse behavioral testing, amygdala LTP electrophysiology, MAPK pathway Western blots, Pak1 genetic intercross, stereotaxic pharmacological injection of Pak1 inhibitors\",\n      \"journal\": \"Nature neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis (Pak1 KO rescue) plus pharmacological rescue with multiple behavioral, electrophysiological, and biochemical readouts\",\n      \"pmids\": [\"25242307\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"MAF is an NF1-regulated transcription factor downstream of RAS/MAPK/AP-1 signaling; MAF re-expression promotes glial differentiation markers and affects MPNST cell death and growth; chronically elevated MAF enhances MPNST tumor growth in vivo through mTOR pathway activation via DEPTOR regulation; RAD001 blocks MAF-mediated tumor growth, establishing a RAS-MAPK→MAF→mTOR crosstalk mechanism.\",\n      \"method\": \"Transcriptome analysis, RT-PCR/Western blot validation, MAF overexpression in MPNST cell lines (inducible), in vivo tumor xenografts, RAD001 treatment, DEPTOR expression analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transcriptome-driven discovery with in vitro and in vivo functional validation plus pharmacological intervention, single lab\",\n      \"pmids\": [\"24509877\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Different NF1 germline mutations (R681X vs. G848R) result in different levels of neurofibromin expression and different optic glioma phenotypes; R681X mutation causes optic glioma formation with increased microglia infiltration and JNK/Ccl5/AKT activation in the microenvironment, while G848R does not; primary astrocytes with R681X show increased basal proliferation comparable to neo-CKO astrocytes, establishing germline mutation type as a cell-autonomous and stromal determinant of glioma development.\",\n      \"method\": \"Genetically engineered mice with patient-derived Nf1 mutations (R681X and G848R conditional KO), optic nerve volumetry/GFAP/BrdU immunostaining, retinal ganglion cell death assay, microglia quantification, phosphoprotein Western blots, primary astrocyte cultures\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two patient-derived knock-in mutations compared side-by-side with multiple cell-autonomous and stromal readouts in genetically engineered mice\",\n      \"pmids\": [\"26908603\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Nf1 deficiency in mature oligodendrocytes causes progressive myelin decompaction and behavioral abnormalities mediated by aberrant Notch activation; blocking Notch, upstream MAPK, or nitric oxide signaling rescues myelin defects in hemizygous Nf1 mutants; gamma secretase inhibition rescues aberrant behavior; active Notch is increased in NF1 patient white matter, establishing Notch as a downstream effector of neurofibromin in oligodendrocyte myelin maintenance.\",\n      \"method\": \"Oligodendrocyte-specific conditional Nf1 knockout mice, myelin ultrastructure analysis, behavioral testing, Notch pathway inhibition (gamma secretase inhibitor), MEK inhibitor, NOS inhibitor, patient white matter immunostaining\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific conditional KO with pharmacological rescue using multiple pathway inhibitors and human patient tissue validation\",\n      \"pmids\": [\"28423318\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"NF1 deficiency in fracture calluses leads to elevated β-catenin protein and activation of β-catenin-mediated signaling, resulting in delayed and fibrous fracture repair; pharmacological inhibition of β-catenin signaling with Nefopam rescues osteoblastic colony formation, bone content, and cartilage in Nf1-/- fracture calluses.\",\n      \"method\": \"Nf1-/- conditional mouse fracture model, β-catenin/Axin2 immunostaining and Western blot in patient and mouse tissue, bone marrow stromal cell osteoblast colony assay, histomorphometry of fracture callus, Nefopam pharmacological treatment\",\n      \"journal\": \"Bone\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO model with biochemical pathway evidence and pharmacological rescue, human tissue corroboration, single lab\",\n      \"pmids\": [\"28254468\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Neurofibromin interacts with CRMP2 and uncouples CRMP2 from syntaxin 1A; loss of neurofibromin (NF1) frees CRMP2 to interact with both syntaxin 1A and CaV2.2, increasing CGRP release and causing pain hypersensitivity; CRISPR/Cas9 editing of Nf1 dysregulates NaV1.7 and CaV2.2, and the CRMP2-derived peptide CNRP1 targeting the CRMP2-neurofibromin interface reverses these ion channel dysregulations and thermal hyperalgesia.\",\n      \"method\": \"Co-immunoprecipitation (CRMP2/neurofibromin/syntaxin 1A/CaV2.2), CRISPR/Cas9 Nf1 editing in rats, neurotransmitter (CGRP) release assay, electrophysiology (NaV1.7, CaV2.2), thermal hyperalgesia behavioral assay, CNRP1 peptide rescue\",\n      \"journal\": \"Neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Co-IP interaction network plus CRISPR KO plus peptide rescue plus electrophysiology and behavior, multiple orthogonal methods\",\n      \"pmids\": [\"29655575\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Nf1 heterozygosity in the microenvironment accelerates formation of benign tumors but impairs malignant transformation, as shown in two orthogonal mouse models; an Nf1+/- microenvironment is tumor-promoting for benign lesions but antagonistic for progression to malignancy, reconciling the roles of NF1 in NF1-syndrome and sporadic cancers.\",\n      \"method\": \"Two independent mouse tumor models (NF1-related and non-NF1-related), conditional genetics, tumor incidence and progression analysis, human tumor data analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two orthogonal genetic mouse models with tumor initiation and progression readouts, single lab\",\n      \"pmids\": [\"30479396\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Full-length neurofibromin forms a high-affinity dimer in vitro and in human cells; biophysical analyses (SEC-MALS, SAXS, SANS, analytical ultracentrifugation) and negative-stain EM reveal the overall dimer architecture; mixing N- and C-terminal protein domains reconstitutes dimer-like structures capable of GTPase activation in vitro; co-expression of the two domains in human cells recapitulates full-length neurofibromin activity.\",\n      \"method\": \"SEC-MALS, small-angle X-ray and neutron scattering, analytical ultracentrifugation, negative-stain EM, in vitro GTPase activation assay, co-IP in human cells, reconstitution from N- and C-terminal fragments\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple structural and biophysical methods with in vitro reconstitution and functional validation of GTPase activity; comprehensive single-study design\",\n      \"pmids\": [\"31836666\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Germline Nf1 mutation in retinal neurons causes aberrantly increased shedding of neuroligin-3 (NLGN3) within the optic nerve in response to retinal neuronal activity; NLGN3 shedding is required for Nf1-driven optic glioma initiation and progression; light deprivation prevents optic glioma formation; genetic Nlgn3 loss or pharmacological NLGN3 shedding inhibition blocks optic glioma formation, establishing neuronal activity–driven NLGN3 shedding as an obligate mechanism downstream of Nf1 mutation.\",\n      \"method\": \"Authenticated Nf1 mouse OPG model, light deprivation experiment, NLGN3 ELISA in optic nerve, Nlgn3 genetic KO rescue, pharmacological ADAM10 inhibitor (NLGN3 shedding inhibition), tumor volume MRI quantification\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic model plus two independent rescue approaches (genetic KO and pharmacological) plus mechanistic biochemical readout, published in high-impact peer-reviewed journal\",\n      \"pmids\": [\"34040258\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Patient variants in NF1 codons 844–848 cause protein instability and exert a dominant-negative effect by destabilizing wild-type neurofibromin through the dimerization interface; cryo-EM structure of neurofibromin was used to predict additional patient variants with similar dominant-negative mechanism, validated experimentally, providing a structural basis for genotype-phenotype correlations.\",\n      \"method\": \"Cryo-EM structure determination, patient variant protein expression and stability assays, co-immunoprecipitation to demonstrate dimerization-dependent dominant-negative effect, computational prediction of destabilizing variants with experimental validation\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — cryo-EM structure combined with mutagenesis, protein stability assays, and Co-IP mechanistic validation\",\n      \"pmids\": [\"36689660\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"Neurofibromin (NF1) is a GTPase-activating protein (GAP) that stimulates hydrolysis of RAS-GTP to RAS-GDP, thereby suppressing RAS/MAPK and PI3K/mTOR signaling; it forms a high-affinity homodimer (with some missense variants acting dominant-negatively through the dimer interface), interacts with CRMP2 to regulate nociceptive ion channels, regulates cAMP homeostasis in neurons via RAS→atypical PKC-ζ→GRK2→Gαs, controls Schwann cell proliferation through cyclin D1, modulates oligodendrocyte myelin integrity via Notch signaling, and requires both cell-autonomous loss (particularly in the Schwann cell/neural precursor lineage) and a haploinsufficient tumor microenvironment (including mast cells and bone marrow–derived cells signaling through c-kit and GM-CSF) for neurofibroma formation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"Neurofibromin (NF1) is a tumor-suppressor GTPase-activating protein whose central activity is to accelerate hydrolysis of RAS-GTP, thereby restraining downstream RAS effector cascades that govern cell proliferation, differentiation, and survival [#1, #11]. GTPase-activating activity is encoded by the GAP-related domain (exons 20–27a), where the R1391S substitution reduces catalytic activity ~300-fold [#1]. Despite sharing in vitro GTPase-activating properties with p120-GAP, neurofibromin exerts distinct biological effects on RAS-driven transcription in cells [#0]. Full-length neurofibromin functions as a high-affinity dimer, and the N- and C-terminal halves reconstitute dimer-like, GTPase-active structures when co-expressed [#30]; patient variants clustered at the dimerization interface (codons 844–848 and others predicted from the cryo-EM structure) destabilize and dominantly inactivate wild-type protein, providing a structural basis for genotype–phenotype correlation [#32]. Through control of RAS, neurofibromin loss deregulates both ERK/MAPK and PI3K/mTOR arms: it antagonizes cAMP accumulation and cyclin D1 to limit Schwann cell proliferation [#7], suppresses BRAF-induced senescence via combined PI3K and ERK deregulation [#18], and gates RAS-ERK attenuation downstream of mutant EGFR to set drug sensitivity in lung cancer [#22]. In the nervous system, neurofibromin couples RAS to cAMP homeostasis through an atypical PKC-ζ→GRK2→Gαs route independent of MEK/AKT [#21], restrains MAPK/PAK1 signaling underlying GABAergic and synaptic deficits [#23], maintains oligodendrocyte myelin through suppression of Notch [#26], and regulates nociceptive ion channels by sequestering CRMP2 away from syntaxin 1A and CaV2.2 [#28]. Neurofibroma genesis requires cell-autonomous NF1 loss in the Schwann cell/neural-precursor lineage together with a haploinsufficient microenvironment, in which mast cells signaling through c-kit and bone marrow–derived cells acting via GM-CSF are essential contributors [#8, #10, #6]. Germline NF1 loss in this disease also drives optic glioma through neuronal-activity–dependent NLGN3 shedding [#31]. NF1 is the gene underlying neurofibromatosis type 1, in which distinct germline mutations confer distinct cell-autonomous and stromal tumor phenotypes [#25].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Established that neurofibromin, although a RAS-GAP, produces biological effects distinct from the canonical p120-GAP, implying a dedicated regulatory role rather than redundancy.\",\n      \"evidence\": \"Microinjection of purified type I NF1 vs. GAP into fibroblasts with AP-1 reporter and DNA-synthesis readouts\",\n      \"pmids\": [\"8455625\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not map the domain responsible\", \"Single lab, indirect readouts of RAS output\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Localized and quantified the catalytic GAP function to the GRD and demonstrated that a single missense mutation cripples activity, linking enzymatic loss to disease-associated variants.\",\n      \"evidence\": \"Site-directed mutagenesis (R1391S), in vitro expression, and direct GAP activity assay\",\n      \"pmids\": [\"9003501\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not address full-length regulation outside the GRD\", \"No structural mechanism for the activity loss\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Revealed isoform-specific and developmentally regulated forms of neurofibromin (type 1 vs type 2, exon 23a) with differing microtubule association, indicating non-GAP functional diversification.\",\n      \"evidence\": \"Northern/Western blot, in situ hybridization, and microtubule co-fractionation across tissues and mouse embryos\",\n      \"pmids\": [\"7794799\", \"7568895\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of microtubule binding undefined\", \"No mechanism linking isoform to RAS activity\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Defined GM-CSF signaling as a required driver of Nf1-deficient myeloproliferation, establishing cytokine dependence of hematopoietic NF1 phenotypes.\",\n      \"evidence\": \"Nf1;Gmcsf double-knockout intercross with adoptive transfer and colony assays\",\n      \"pmids\": [\"10678181\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not connect to solid-tumor microenvironment\", \"Mechanism of GM-CSF hypersensitivity at the receptor level not resolved\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Placed cyclin D1 and cAMP downstream of Nf1 in Schwann cell growth control, identifying a concrete cell-cycle effector of neurofibromin loss.\",\n      \"evidence\": \"Inducible cyclin D1 retroviral expression, cAMP and BrdU assays in Nf1-/- vs WT Schwann cells\",\n      \"pmids\": [\"11160381\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Link from RAS to cAMP not yet mechanistically defined\", \"Restricted to Schwann cell lineage\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Demonstrated that Schwann cell-autonomous NF1 loss plus a heterozygous microenvironment is the combination required for neurofibroma formation, defining a two-compartment tumor model.\",\n      \"evidence\": \"Krox20-Cre conditional Nf1 knockout on Nf1+/- background with tumor histology\",\n      \"pmids\": [\"11988578\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the contributing stromal cell type unknown\", \"Microenvironmental signals not yet defined\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Showed NF1 expression is subject to CTCF-dependent long-range interchromosomal regulation, adding a transcriptional control layer.\",\n      \"evidence\": \"3C, FISH, CTCF knockdown and ICR-deletion mouse with Wsb1/Nf1 expression analysis\",\n      \"pmids\": [\"16614224\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relevance to human NF1 disease unestablished\", \"Single-locus mechanism, magnitude of expression effect modest\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identified mast cells, c-kit signaling, and an EGFR-dependent nerve progenitor pool as the cellular and receptor mediators of the neurofibroma microenvironment and cell of origin.\",\n      \"evidence\": \"Bone marrow transplantation, c-kit intercross, imatinib, DhhCre conditional KO, sphere assays, and human EGFR+/P75+ cell xenografts\",\n      \"pmids\": [\"18984156\", \"19041782\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative contribution of each compartment unclear\", \"How NF1-null Schwann cells recruit mast cells not yet defined\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identified skin-derived precursors as the cell of origin for dermal neurofibromas, refining the lineage in which NF1 loss initiates tumors.\",\n      \"evidence\": \"P0-Cre conditional Nf1 loss in SKPs with lineage tracing and transplantation\",\n      \"pmids\": [\"19427294\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Microenvironmental signals defined only as 'additional'\", \"Relation to plexiform neurofibroma origin not addressed\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Connected NF1 loss to mTOR survival dependency in AML and defined the SCF/Kit ligand–PI3K axis by which Nf1-/- Schwann cells provoke mast cell degranulation.\",\n      \"evidence\": \"Ras-GTP pulldown, shRNA, rapamycin sensitivity in AML blasts; conditioned-medium degranulation with Nf1/PI3K intercrosses\",\n      \"pmids\": [\"20505189\", \"21037083\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"mTOR dependency tested ex vivo only\", \"Whether SCF-PI3K loop is generalizable across tumor stages unclear\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Showed that timing and Schwann cell subtype of NF1 loss dictate neurofibroma onset and size, and confirmed non-cell-autonomous lympho-hematopoietic expansion.\",\n      \"evidence\": \"Tamoxifen-inducible PlpCre;Nf1fl/fl with EGFP lineage tracing across perinatal vs adult induction\",\n      \"pmids\": [\"21551249\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular basis of differing tumor kinetics unresolved\", \"Why GFAP+ non-myelinating cells are exempt unknown\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Established NF1 as a cooperating tumor suppressor in melanoma that prevents oncogene-induced senescence and sets BRAF-inhibitor sensitivity through dual PI3K/ERK control.\",\n      \"evidence\": \"BRAF+Nf1 mouse model, senescence and proliferation assays, pathway biochemistry, BRAF-inhibitor sensitivity in cell lines\",\n      \"pmids\": [\"23171796\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative weighting of PI3K vs ERK contribution unresolved\", \"Does not address other sporadic cancer contexts\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Extended neurofibromin function beyond tumor suppression into muscle energy metabolism and vascular neointima formation via Ras-Erk in macrophages.\",\n      \"evidence\": \"Muscle-specific Nf1 KO with metabolic/enzymatic assays; Nf1+/- carotid injury model with MEK-inhibitor rescue\",\n      \"pmids\": [\"24163128\", \"24211110\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct RAS substrate link in muscle metabolism not shown\", \"Cell-autonomous vs systemic metabolic effects not separated\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Resolved neuron-specific and tumor-specific effector branches: a RAS→PKC-ζ→GRK2→Gαs cAMP route, a MAPK/PAK1 synaptic axis, and a RAS-MAPK→MAF→mTOR crosstalk in MPNST; also defined NF1 control of EGFR-driven RAS-ERK attenuation.\",\n      \"evidence\": \"iPSC neural progenitors and Nf1 mice (cAMP); Pak1 KO/inhibitor amygdala rescue; MAF/DEPTOR overexpression with RAD001; genome-wide siRNA screen with MEK-inhibitor rescue\",\n      \"pmids\": [\"25070947\", \"25242307\", \"24509877\", \"24535670\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How a single GAP selects distinct effector branches across cell types unknown\", \"MAF transcriptional targets only partially mapped\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Demonstrated that the specific germline NF1 mutation, via differing residual protein levels, determines both cell-autonomous proliferation and stromal glioma phenotype.\",\n      \"evidence\": \"Patient-derived R681X vs G848R knock-in mice with optic nerve, microglia, and astrocyte readouts\",\n      \"pmids\": [\"26908603\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking residual neurofibromin level to microglial activation incomplete\", \"Generalizability to other variants untested here\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified Notch and Wnt/β-catenin as tissue-specific downstream effectors of neurofibromin in oligodendrocyte myelin maintenance and fracture repair.\",\n      \"evidence\": \"Oligodendrocyte-specific Nf1 KO with γ-secretase/MEK/NOS inhibitor rescue and patient tissue; Nf1-/- fracture model with β-catenin readouts and Nefopam rescue\",\n      \"pmids\": [\"28423318\", \"28254468\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct biochemical link from RAS to Notch/β-catenin not established\", \"Whether effects are GAP-dependent untested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Established a non-canonical neurofibromin function in pain signaling through CRMP2 sequestration controlling NaV1.7/CaV2.2 and CGRP release.\",\n      \"evidence\": \"Co-IP network, CRISPR Nf1 editing, electrophysiology, CGRP release, and CNRP1 peptide rescue with behavior\",\n      \"pmids\": [\"29655575\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CRMP2 interaction is GAP-domain dependent unclear\", \"Human translation of CNRP1 rescue not addressed\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Determined that full-length neurofibromin is an obligate high-affinity dimer reconstitutable from N- and C-terminal halves, defining its quaternary structure and a route to GTPase activation.\",\n      \"evidence\": \"SEC-MALS, SAXS/SANS, AUC, negative-stain EM, in vitro GTPase assay, and fragment reconstitution in cells\",\n      \"pmids\": [\"31836666\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Atomic-resolution interface not yet defined at this stage\", \"Regulatory role of dimerization in vivo unaddressed\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showed that NF1-driven optic glioma requires neuronal-activity–dependent NLGN3 shedding, defining an obligate non-cell-autonomous initiation mechanism.\",\n      \"evidence\": \"Nf1 OPG mouse model with light deprivation, Nlgn3 KO, and ADAM10 shedding-inhibitor rescue plus MRI tumor quantification\",\n      \"pmids\": [\"34040258\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Link from neurofibromin loss to NLGN3 shedding sensitization not fully mechanistic\", \"Restricted to optic pathway gliomas\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Provided a cryo-EM structural basis for dominant-negative NF1 variants that destabilize wild-type neurofibromin via the dimer interface, enabling variant prediction.\",\n      \"evidence\": \"Cryo-EM structure, codon 844–848 variant stability assays, Co-IP, and computational prediction with experimental validation\",\n      \"pmids\": [\"36689660\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Clinical penetrance of predicted variants not established\", \"Functional consequence on RAS output in patient cells not measured\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How a single dimeric RAS-GAP selects among its distinct cell-type-specific effector branches (cAMP/PKC-ζ, Notch, β-catenin, CRMP2, MAF-mTOR) and how dimerization is dynamically regulated in vivo remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No unifying mechanism linking GAP activity to non-RAS effector engagement\", \"Regulation of dimer assembly/disassembly in cells unknown\", \"Whether non-GAP functions require dimerization untested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 1, 30]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [7, 18, 21, 22]},\n      {\"term_id\": \"GO:0140313\", \"supporting_discovery_ids\": [28]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [2, 3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [2, 3]},\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [2, 3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 18, 22]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [8, 10, 14, 18]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [12, 13, 26]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [21, 23, 28]}\n    ],\n    \"complexes\": [\"neurofibromin homodimer\"],\n    \"partners\": [\"CRMP2\", \"STX1A\", \"CACNA2 (CaV2.2)\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":9,"faith_total":9,"faith_pct":100.0}}